Arcutis Biotherapeutics 

Yahoo Finance • 8 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the... Full story

Yahoo Finance • 12 days ago

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025... Full story

Yahoo Finance • 13 days ago

Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% in 2025

Biotech leader Arcutis stock is breaking out past its latest buy point. Shares are up nearly 36% in 2025. Continue Reading View Comments... Full story

Yahoo Finance • 25 days ago

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin typesNew data show improved quality of life and decreased impact on families for investigational ZORYVE... Full story

Yahoo Finance • 26 days ago

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum

In the world of growth investing, combining technical strength with fundamental momentum often yields promising candidates. One approach gaining traction is the integration of Mark Minervini’s Trend Template with high growth momentum (HGM)... Full story

Yahoo Finance • last month

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogsZORYV... Full story

Yahoo Finance • last month

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide exp... Full story

Yahoo Finance • 2 months ago

Arcutis to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced th... Full story

Yahoo Finance • 2 months ago

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum

SPOTTING HIGH-GROWTH STOCKS USING THE MINERVINI TREND TEMPLATE Mark Minervini’s Trend Template is a structured method for finding stocks in strong upward trends, blending technical and fundamental factors to select promising options. The... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts

Arcutis Biotherapeutics reported its earnings for the second quarter of 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.13, beating the forecast of -$0.17, and reported revenue of $81.... Full story

Yahoo Finance • 3 months ago

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced th... Full story

Yahoo Finance • 3 months ago

Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise

Executive Vice President and Chief Medical Officer Patrick Burnett of Arcutis Biotherapeutics (NASDAQ:ARQT), a $1.89 billion market cap biopharmaceutical company with impressive 88% gross margins, sold 28,750 shares of common stock for app... Full story

Yahoo Finance • 4 months ago

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with ZORYVE cream 0.15% or... Full story

Yahoo Finance • 4 months ago

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced tha... Full story

Yahoo Finance • 4 months ago

Analysts Anticipate 25% Gains Ahead For The Holdings of FHLC

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of useMore than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involv... Full story

Yahoo Finance • 5 months ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) S... Full story

Yahoo Finance • 6 months ago

Arcutis Announces Chief Financial Officer Transition

WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced t... Full story

Yahoo Finance • 6 months ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to ann... Full story